We are excited to announce that effective today we have modified our Regulation A+ equity crowdfunding offering. As a result of the tremendous advancements we have made in our labs, the price per share will be increasing to $13.50 per share, which represents a 35% increase in share price since our original offering.
Last week we announced a groundbreaking milestone – BIOLIFE4D has successfully bioengineered a 3D bio-printed mini-heart. And as a result in just the past week we have received worldwide media recognition from publications including, Forbes, Digital Trends Live, NBC, ABC, Yahoo Finance, Crain’s Chicago, Engadget, and many more.
We’re truly overwhelmed by and appreciate the incredible support we’ve already received from our investors – without you, we wouldn’t have been able to have achieved so much so quickly. But our story is still only just beginning, and as we continue advancing forward and reaching additional scientific milestones, we look forward to continuing increasing shareholder value.
To learn more about BIOLIFE4D or to express interest in investing, please visit our website. Please also continue to follow our story on social media, connect with us on Facebook, LinkedIn and Twitter, and please help spread the word about BIOLIFE4D and our mission by sharing our story throughout your network.
Together, we’ve already taken a significant step towards addressing the global killer that takes one out of every three lives globally – cardiovascular disease. And together, we will bring our incredible technology to the market and save countless lives.
Thank you to everyone for your overwhelming support – the best is yet to come.